Active immunotherapy in the treatment of haematological neoplasias
Idiotypic vaccine
Dendritic cells
Follicular lymphoma
Issue Date: 
Gobierno de Navarra. Departamento de Salud
Inoges S, Rodriguez Calvillo M, Lopez Diaz de Cerio A, Zabalegui N, Melero I, Sanchez Ibarrola A, et al. Active immunotherapy in the treatment of haematological neoplasias. An Sist Sanit Navar 2004 Jan-Apr;27(1):45-62.
Abstract The continuous search for therapeutic approaches that improve the conventional treatments of neoplasms, together with an improved understanding of the immune system, has led in recent years to the development of Immunotherapy. Basically, a distinction can be made between two forms of immunotherapy: passive immunotherapy, which consists in the transfer of antibodies or cells previously generated in vitro that are directed against the tumour, and active immunotherapy, which attempts to activate in vivo the immune system and induce it to elaborate a specific response against the tumor antibodies. Hematological neoplasms, specifically some B lymphomas, express in their membrane an immunoglobulin that is considered a specific antigen of the tumour, which is why these diseases have become the ideal target for immunotherapy treatments. There are many alternatives, ranging from protein vaccines, which have already shown clinical benefits, to those of the second generation, which make use of the new techniques of molecular biology to increase the efficacy of the vaccines and obtain their production in a quicker and less costly way, but with which there are not yet definitive clinical results.

Files in This Item:
An Sist Sanit Navar_27 2004.pdf
137.22 kB
Adobe PDF

Statistics and impact
0 citas en
0 citas en

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.